Health ❯ Pharmaceuticals ❯ Clinical Trials

Drug Development

Regulatory Compliance Regulatory Affairs MASH Treatment Regulatory Issues Phase 3 Trials Investor Impact Fasedienol Safety Concerns GLP-1 Agonists BioAge Labs, Inc. Lung Cancer Treatments Azelaprag Prostate Cancer Therapeutic Areas Social Anxiety Disorder Syntis Bio FDA Approval Investigational Drugs Nimacimab Avexitide

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

Amylyx plans a year‑end FDA filing that could lead to a 2027 launch funded by a new equity offering.

Law Firm Seeks Nektar Investors to Lead Securities Suit Over REZOLVE‑AA Trial Claims

Vistagen Investors Face March 16 Lead‑Plaintiff Deadline as Law Firms Seek Clients

Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

aTyr Investors Face Dec. 8 Deadline in Securities Suits Over Efzofitimod Trial Failure

aTyr Investors Face Dec. 8 Deadline as Rival Lawsuits Over Failed Sarcoidosis Trial Intensify

Jasper Therapeutics Investors Face Lead Plaintiff Deadline in Securities Class Action

New aTyr Class Action Expands Investor Window After EFZO-FIT Failure

Law Firms Urge Jasper Therapeutics Investors to Seek Lead‑Plaintiff Role Before Nov. 18 Deadline